The impact of the global coronavirus (COVID-19) outbreak has been rapidly evolving, causing disruption in global commerce across a wide range of industries. Private fund managers are not immune to the disruption. According to PitchBook’s latest analysis, private equity and venture ­­capital still have record amounts of dry powder ($2.4 trillion) to weather the storm and step in to provide liquidity to businesses. However, operations, fundraising, deal sourcing, and performance will likely be negatively affected, at least in the near-term, by the economic deterioration caused by COVID-19.

The sharp decline in the economy will cause ripple effects throughout the ecosystem. A few consequences to prepare for:

Challenges Stemming from Liquidity Concerns

  • As liquidity becomes a concern, fundraising for new funds may be challenged, particularly as large institutional investors see their alternatives allocation become overweighted in comparison to the rest of their investment portfolio. GPs may try to expedite fundraising on an accelerated timeline, trying to lock down commitments before a potential recession hits. Other GPs may delay fundraising, hoping that the impact of COVID-19 lessens sooner than later.
  • GPs may also make capital calls earlier than anticipated because of concern over LPs’ liquidity. However, if capital calls are made with no investment intent in mind, even if allowed under the relevant LPA, the sponsor will be trading liquidity for fund performance as LPs’ IRRs would be negatively impacted.
  • LPs may consider pulling back from verbal investment commitments to new funds for various reasons. For example, certain investors, like pension plans, may project fewer plan contributions and/or investment distributions than usual and therefore have less capital to allocate to investments.
  • Some portfolio companies may be under significant financial pressure, especially where their business models have been negatively impacted by governmental orders to close non-essential business – travel, leisure, retail, hospitality, gaming, sports and many others have all been disrupted.

Uncertainty Leading to Commercial Disputes

  • One phrase that we are hearing more frequently is “force majeure.” Force majeure provisions excuse performance due to events beyond the parties’ control.  Whether the coronavirus can trigger a “force majeure” excuse at this point in time is an open question though, historically, economic hardship by itself is an insufficient reason to excuse performance.
  • “Material adverse effect” or MAE clauses may excuse performance under certain circumstances. These clauses are often heavily negotiated and vary significantly deal-by-deal, and therefore must be evaluated on a case-by-case basis.

Business Continuity Planning

The SEC’s exam staff has started reaching out to fund managers asking what their Business Continuity Plans look like. Managers must consider whether they are prepared to have all personnel work remotely for an extended period of time and assess whether there are business operations that cannot be performed remotely or have not performed as previously anticipated.

Out of an abundance of caution, GPs should consider putting power of attorney rights in place for key people at the fund.

Regulatory Issues for Fund Sponsors

The SEC can be expected to examine how fund managers respond to the crisis and whether their responses were consistent with their fiduciary duties.   Any deficiencies that may have been overlooked and potentially hidden by the strong economy are likely to be scrutinized.

  • Economic impacts may adversely affect the performance of a fund’s investments. Managers should consider adding risk factors related to recent developments.
  • The SEC will likely look at whether a fund manager made false or misleading statements to its limited partners, investors or clients regarding the severity of the impact of the crisis on its funds.
  • Valuation of privately-held investments will be a key area of focus, particularly the process surrounding potential write downs and related presentations or reporting to investors.
  • The SEC will also likely examine whether, in responding to the crisis, a fund manager took measures to benefit itself or certain investment vehicles at the expense other limited partners.

The current crisis brings to mind the Warren Buffett quote that “only when the tide goes out do you discover who’s swimming naked.” We are already seeing distress that was not even on the horizon a few weeks ago.   The tide is going out and managers’ actions, including matters that may be entirely unrelated to the coronavirus, may be scrutinized in an economic downturn.

We will continue to monitor the ever-evolving landscape as COVID-19 developments continue. In the meantime, Proskauer is here to answer any of your questions or concerns and help avoid disputes.

*          *          *

Proskauer’s cross-disciplinary, cross-jurisdictional Coronavirus Response Team is focused on supporting and addressing client concerns. Visit our Coronavirus Resource Center for guidance on risk management measures, practical steps businesses can take and resources to help manage ongoing operations.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Hena M. Vora Hena M. Vora

Hena M. Vora is an associate in the Litigation Department and a member of the Asset Management Litigation, Trials, Mass Torts & Product Liability, and Consumer Litigation practices, as well as the Real Estate Litigation group. Her practice encompasses a range of complex…

Hena M. Vora is an associate in the Litigation Department and a member of the Asset Management Litigation, Trials, Mass Torts & Product Liability, and Consumer Litigation practices, as well as the Real Estate Litigation group. Her practice encompasses a range of complex civil and commercial litigation matters, including securities litigation, partnership disputes, and consumer products.

Hena has experience with various stages of litigation, including pitching clients, coordinating discovery, drafting dispositive motions and trial memoranda, handling court conferences, taking and defending depositions, and preparing witnesses for depositions and trial. She also has experience conducting highly sensitive and confidential internal investigations. Hena was part of two trial teams that secured complete defense verdicts on behalf of Monsanto in high-profile product liability actions. She also helped secure a complete dismissal at the trial court and appellate levels on behalf of a prominent private fund client, defending against claims of breach of fiduciary duty, aiding and abetting, and unjust enrichment.

Hena serves as the president of the South Asian Bar Association of New York (SABANY). She also maintains an active pro bono practice and has been awarded for creating a partnership between Proskauer’s Boston office and Minds Matter Boston, through which she helps high school students from low-income backgrounds achieve college readiness and success.

Hena earned her J.D. from Emory University School of Law, where she received the Pro Bono Publico honor and a Transactional Law Certificate. In addition, she was a national competitor on the Moot Court Society and served as president of Emory’s South Asian Law Students Association. While at Emory, Hena served as judicial intern for Judge Denny Chin at the U.S. Court of Appeals for the Second Circuit.

Photo of Joshua M. Newville Joshua M. Newville

Joshua M. Newville is a partner in the Litigation Department and a member of Proskauer’s White Collar Defense & Investigations Group and the Asset Management Litigation team.

Josh handles securities litigation, enforcement and regulatory matters, representing corporations and senior executives in civil and…

Joshua M. Newville is a partner in the Litigation Department and a member of Proskauer’s White Collar Defense & Investigations Group and the Asset Management Litigation team.

Josh handles securities litigation, enforcement and regulatory matters, representing corporations and senior executives in civil and criminal investigations. In addition, Josh advises registered investment advisers and private fund managers on regulatory compliance, SEC exams, MNPI/insider trading and related risks.

Before joining Proskauer, Josh was senior counsel in the U.S. Securities and Exchange Commission’s Division of Enforcement, where he investigated and prosecuted violations of the federal securities laws. Josh served in the Enforcement Division’s Asset Management Unit, a specialized unit focusing on investment advisers and the asset management industry. His prior experience with the SEC provides a unique perspective to help asset managers manage risk and handle regulatory issues.

Photo of Michael R. Hackett Michael R. Hackett

Mike Hackett is a partner in the Litigation Department and Co-Head of the Asset Management Litigation practice. An experienced litigator and trial lawyer, Mike’s practice focuses on complex commercial litigation, with a particular emphasis on asset management, financial services, M&A, shareholder, and life…

Mike Hackett is a partner in the Litigation Department and Co-Head of the Asset Management Litigation practice. An experienced litigator and trial lawyer, Mike’s practice focuses on complex commercial litigation, with a particular emphasis on asset management, financial services, M&A, shareholder, and life sciences disputes.

A significant portion of Mike’s practice concerns disputes and regulation involving private funds, including private equity, venture capital, hedge, real estate and private credit funds, as well as their sponsors, partners, investors, portfolio companies, and officers and directors. Mike’s experience representing private fund clients runs the gamut, from control contests within advisers, to disputes between limited partners and general partners, to representation of investment advisers in connection with regulatory examinations, investigations and enforcement matters. Mike routinely represents funds, fund sponsors, portfolio companies, and their officers and directors, including in significant post-closing M&A disputes.

Mike also litigates high-stakes commercial disputes in the life sciences and financial services areas, including for established pharmaceutical and biotechnology companies, emerging and innovative start-ups, asset managers, and other private capital investors, in areas such as M&A, breach of contract, indemnification, fraud, contested earnouts and royalties, securities and capital markets, and corporate governance.

Mike has been recognized by Chambers USA and was named a “Rising Star” by Massachusetts Super Lawyers.